Illumina Appoints Christian Henry to Newly Created Position of Senior Vice President of Corporate Development

SAN DIEGO–Illumina, Inc. (NASDAQ:ILMN) today announced that Christian Henry has assumed the newly created role of Senior Vice President of Corporate Development. In this role, Mr. Henry is responsible for all activities related to corporate and business development, strategic planning, and mergers and acquisitions.

“Christian has done an outstanding job as CFO, building a world-class finance organization, successfully raising more than $850 million, and helping to integrate multiple acquisitions,” said Jay Flatley, president and CEO. “He successfully led our Sequencing Business for more than 14 months and demonstrated both his interest and capability to assume broader operating responsibilities. I look forward to working with Christian in this new role to plan and build the future Illumina,” Flatley added.

Mr. Henry will immediately assume his new role while continuing to operate as Illumina’s CFO. The company intends to begin an immediate search for a new CFO.

“As we continue our rapid growth, rigorous planning and effective evaluation, balancing and execution of both organic and inorganic growth options will become increasingly important,” said Dr. William Rastetter, Illumina’s Chairman of the Board. “Christian’s leadership skills combined with his understanding of Illumina’s markets and strategies make him ideally suited to lead our Corporate Development effort.”

“I am excited to undertake this new role with the goal of building a strong corporate development function and working with Jay, our Board of Directors and the management team to drive the evolution and execution of Illumina’s strategy,” said Christian Henry. “In addition, I look forward to recruiting and working with a world-class financial executive in the CFO position.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, DNA analysis, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and DNA analysis products and applications for our technology platforms, (iii) to manufacture robust microarrays and Oligator® oligonucleotides, (iv) to integrate and scale our VeraCode technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.